Belite Bio, Inc
BLTE Nasdaq· Pharmaceutical Preparations
Last close · Nov 9, 2026
$157.69
Key numbers, fiscal 2025
Market cap
$5.3B
P/E
—
Revenue
—
Net income
−$77.6M
Free cash flow
−$37.1M
Operating margin
—
Belite Bio, Inc in 30 seconds fiscal 2025
Does it make a profit?
−$77.6M
No. It lost money last year.
How long would its cash last?
9.5 yrs
Comfortably. It burns $37.1M a year and holds $353M, about 9.5 years at that pace.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Belite Bio, Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 31, 2026
- Legal name
- BELITE BIO, INC
- CIK
- 0001889109
Belite Bio, Inc · BLTE · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$9.7M | −$12.6M | −$31.6M | −$36.1M | −$77.6M |
| Diluted EPS | −$1.01 | −$0.63 | −$1.19 | −$1.18 | −$2.31 |
| Cash | |||||
| Cash from operations | −$7.5M | −$11.5M | −$29.8M | −$29.2M | −$37.0M |
| Capital expenditure | $0.1M | $0.4M | $0.1M | $0.1M | $0.1M |
| Free cash flow | −$7.5M | −$11.9M | −$29.9M | −$29.4M | −$37.1M |
| Share count change | 8.9% | 108.7% | 33.1% | 14.8% | 9.8% |
| Debt and strength | |||||
| Cash and short-term investments | $17.3M | $42.1M | $88.2M | $36.2M | $353M |
| Shareholders' equity | −$15.1M | $41.5M | $90.4M | $146M | $770M |
| Current ratio | 10.7x | 20.3x | 24.8x | 24.3x | 50.0x |
| Interest coverage | — | −801.3x | −1,266.7x | −1,999.8x | −42,104.0x |
| Returns and quality | |||||
| Return on equity | — | −95.8% | −48.0% | −30.6% | −16.9% |
| Return on tangible equity | — | −30.5% | −35.0% | −24.8% | −10.1% |
| Altman Z'' | −12.5 | 16.9 | 23.8 | 26.3 | 82.9 |
Insider trades 12 months
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$40.6M
5 insiders
Of sales under plans
93%
$37.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Belite Bio, Inc · BLTE · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001889109). Latest version: stoqly.net/companies/blte. Data updated November 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.